- Home
- ZNTL vs BRBI Comparison
ZNTL vs BRBI Comparison
Compare ZNTL & BRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZNTL | BRBI |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | 188 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.9M | 383.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZNTL | BRBI |
|---|---|---|
| Price | $3.92 | $15.91 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.60 | N/A |
| AVG Volume (30 Days) | ★ 4.2M | 4.6K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 4.64% |
| EPS Growth | ★ 18.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.24 |
| P/E Ratio | ★ N/A | $11.72 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $12.54 |
| 52 Week High | $6.95 | $67.01 |
Technical Indicators
Market Signals| Indicator | ZNTL | BRBI |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 56.23 |
| Support Level | $1.53 | $13.77 |
| Resistance Level | $3.95 | $16.46 |
| Average True Range (ATR) | 0.77 | 0.42 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 30.87 | 72.59 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About BRBI BRBI BR Partners S.A. ADSs
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.